UBS Group downgraded shares of Cytokinetics (NASDAQ:CYTK – Free Report) from a buy rating to a neutral rating in a report published on Wednesday, Marketbeat.com reports. They currently have $92.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $61.00. Other research analysts also recently issued research reports about the […]
UBS Group downgraded shares of Cytokinetics (NASDAQ:CYTK – Free Report) from a buy rating to a neutral rating in a research note published on Wednesday, Marketbeat.com reports. The brokerage currently has $92.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $61.00. Other research analysts also recently issued reports about […]
UBS Group downgraded shares of Cytokinetics (NASDAQ:CYTK – Free Report) from a buy rating to a neutral rating in a research note released on Wednesday, Marketbeat Ratings reports. UBS Group currently has $92.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $61.00. A number of other research analysts also […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock investors acquired 267,109 call options on the stock. This represents an increase of 1,648% compared to the typical daily volume of 15,277 call options. Cytokinetics Price Performance Shares of CYTK opened at $84.95 on Friday. Cytokinetics […]
StockNews.com lowered shares of Cytokinetics (NASDAQ:CYTK – Free Report) from a hold rating to a sell rating in a report published on Friday. A number of other analysts have also commented on the stock. Needham & Company LLC lifted their target price on shares of Cytokinetics from $60.00 to $108.00 and gave the stock a […]